Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ophthalmic drug approvals, compounding economics, and FDA milestones make Harrow Health’s disclosures dense reading. If you have ever searched for “Harrow Health SEC filings explained simply” or wished for a “Harrow Health annual report 10-K simplified,” you know how quickly technical jargon slows real analysis. Stock Titan’s AI-driven platform opens every Harrow filing with context, highlighting how its Dextenza distribution agreements, in-office sedation products, and research expenses shape long-term value.
Need the numbers fast? Our tool streams each “Harrow Health quarterly earnings report 10-Q filing” the moment it hits EDGAR, then produces a concise “Harrow Health earnings report filing analysis” that isolates revenue per ophthalmic segment, compounding margins, and cash runway. It also decodes Form 8-K notices—think “Harrow Health 8-K material events explained”—so you instantly see how licensing deals or FDA complete response letters may move the stock. In short, you’re “understanding Harrow Health SEC documents with AI,” not digging through footnotes.
Monitoring management behavior is just as effortless. Receive alerts for “Harrow Health insider trading Form 4 transactions,” review “Harrow Health Form 4 insider transactions real-time,” and compare option grants under the “Harrow Health executive stock transactions Form 4” label. Preparing for the annual meeting? Our AI highlights board pay metrics inside every “Harrow Health proxy statement executive compensation” section. From 10-K to 8-K, Stock Titan delivers complete coverage, real-time updates, and expert clarity—so you spend time acting on insights, not hunting for them.
Harrow, Inc. director/officer Francis William Mullery Jr. reported an initial beneficial ownership filing dated
Harrow, Inc. submitted a Form 25 notification concerning removal of its registered class of securities from the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. The filing identifies the issuer's principal office in Nashville, Tennessee, and includes a contact telephone number. The document lists the standard regulatory rule checkboxes for striking a listing but does not indicate which specific rule provision was selected or provide an effective delisting date.
The filing states that Nasdaq certifies it has complied with exchange rules to strike the securities and that the issuer has complied with exchange requirements governing voluntary withdrawal, where applicable. Other than procedural certification and administrative details (including an OMB control number), the filing contains no financial results, transactions, or reasons for the removal.
Nasdaq Stock Market LLC has filed a Form 25 notification to remove the class of securities of Harrow, Inc. (HROW) from listing and/or registration on the Nasdaq exchange. The filing identifies the issuer and exchange and certifies Nasdaq believes it meets the requirements to submit this notice. The document does not include a signed signature block or detail which rule provision was checked for the removal.
Harrow, Inc. and certain subsidiaries entered into a new senior secured revolving credit agreement with Fifth Third Bank providing an initial facility of $40.0 million and an uncommitted incremental revolving line up to $20.0 million. The facility is secured and includes subsidiary guarantors, and it matures on September 26, 2030 or, if earlier, 91 days prior to the earliest maturity date of the company’s 8.625% senior notes due 2030. The credit line increases the company’s committed liquidity and provides flexibility through an additional uncommitted incremental option; the agreement names Fifth Third as administrative agent, letter of credit issuer, swing line lender, lead arranger and bookrunner.
Harrow, Inc. (HROW) filed a Form 4 disclosing a stock option grant to Chief Accounting Officer Randall E. Pollard. On 09/01/2025 Mr. Pollard was granted an option to purchase 30,000 shares of common stock at an exercise price of $39 per share. The option expires on 09/01/2035 and is exercisable according to a vesting schedule: 25% at the one-year anniversary and the remainder vesting in 12 equal quarterly installments, becoming fully vested and exercisable on 09/01/2029. The filing was signed by an attorney-in-fact on 09/09/2025.
Randall E. Pollard, the Chief Accounting Officer of Harrow, Inc. (HROW), filed an initial Form 3 reporting that he does not beneficially own any securities of the company. The event requiring the statement is dated
FAQ
What is the current stock price of Harrow Health (HROW)?
What is the market cap of Harrow Health (HROW)?
